Planta Med 2011; 77(16): 1769-1773
DOI: 10.1055/s-0030-1271135
Biological and Pharmacological Activity
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

Astilbin Attenuates Hyperuricemia and Ameliorates Nephropathy in Fructose-Induced Hyperuricemic Rats

Lvyi Chen1 , Zhou Lan2 , Yongqiang Zhou1 , Fei Li1 , Xin Zhang1 , Chunfeng Zhang1 , Zhonglin Yang1 , Ping Li1
  • 1Key Laboratory of Modern Chinese Medicines, China Pharmaceutical University, Ministry of Education, Nanjing, P. R. China
  • 2Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, Nanjing, P. R. China
Further Information

Publication History

received Nov. 20, 2010 revised March 22, 2011

accepted April 26, 2011

Publication Date:
25 May 2011 (online)

Preview

Abstract

Astilbin is a flavonoid compound isolated from the rhizome of Smilax china L. The effects and possible mechanisms of astilbin on hyperuricemia and nephropathy rats were elucidated in this study. Different dosages of astilbin (1.25, 2.5, and 5.0 mg/kg) were administered to 10 % fructose-induced hyperuricemic rats. The results demonstrated that astilbin significantly decreased the serum uric acid (Sur) level by increasing the urinary uric acid (Uur) level and fractional excretion of urate (FEUA) but not inhibiting the xanthine oxidase (XOD) activity. In addition, kidney function parameters such as serum creatinine (Scr) and blood urea nitrogen (BUN) were recovered in astilbin-treated hyperuricemic rats. Further investigation indicated that astilbin prevented the renal damage against the expression of transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) and also exerted a renal protective role by inhibiting formation of monosodium urate (MSU) and production of prostaglandin E2 (PGE2) and interleukin-1 (IL-1). These findings provide potent evidence for astilbin as a safe and promising lead compound in the development of a disease-modifying drug to prevent hyperuricemia and nephropathy.

Supporting Information

References

Chunfeng Zhang

Key Laboratory of Modern Chinese Medicines
China Pharmaceutical University

No. 24 Tongjia Lane

Nanjing City 210009

P. R. China

Phone: +86 25 83 27 14 26

Fax: +86 25 83 27 14 26

Email: zhangchunfeng67@163.com

Zhonglin Yang

Key Laboratory of Modern Chinese Medicines
China Pharmaceutical University

No. 24 Tongjia Lane

Nanjing City 210009

P. R. China

Phone: +86 25 83 27 14 26

Fax: +86 25 83 27 14 26

Email: zlyang1950@yahoo.cn